Uvax Bio is a leading biotech pharmaceutical company specializing in the development and commercialization of prophylactic vaccines. Founded in 2018, it has quickly emerged as a global leader in the vaccine industry, aiming to address unmet public health needs. Uvax Bio's breakthrough proprietary technology, the 1c-SA p NP® platform, is the result of years of research by Dr.

Jiang Zhu and his team at Scripps Research. This innovative technology combines rational antigen design and protein engineering to create highly effective virus-like particle vaccines. Uvax Bio's vaccine pipeline is focused on tackling the most challenging infectious diseases.

Currently, their main focus is the development of an HIV-1 vaccine, with Phase 1 trials slated to begin in 2022. In addition to HIV-1, Uvax Bio has three other vaccine assets in research cell bank development. With a strong vision to improve global health, Uvax Bio is committed to supporting humanity through their safe and effective vaccine solutions.

For more information or to get in touch with Uvax Bio, visit their website or connect with them on LinkedIn